Arrowhead Pharmaceuticals, Inc.
NASDAQ:ARWRBiotechnology
+$4.49 today
- Market cap
- $6.09B
- Beta
- 1.27
- P/E (TTM)
- -38.4
- EPS (TTM)
- -$2.11
Volume 2.42M
Average 1.82M
ARWR Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Arrowhead Pharmaceuticals, Inc.NASDAQ: ARWR
Capital Expenditures · Q4 FY2026 · quarter ended Sep 2026
Capital expenditures declines year over year
Q4 FY2026 capital expenditures of $3.43M (cash outflow) fell 54.2% year over year, behind the -47.1% change in trailing-twelve-month capital expenditures. Sequentially, it fell 11.1% from the prior quarter. Over 3 fiscal years it compounded at -59.2% a year.
Context
- Capital expenditures amounted to 2.7% of revenue in FY2026, unchanged from a year earlier.
- Capital expenditures grew in size in 0 of the last 3 fiscal years.
- FY2026 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -54.2% toward the trailing-twelve-month pace of -47.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2026
- (12M) USD
- Year-over-year change
- +47.1%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2026 | 2026-09-30 | (12M) | +47.1% |
| FY2025 | 2025-09-30 | (22.67M) | +84.0% |
| FY2024 | 2024-09-30 | (141.47M) | +20.0% |
| FY2023 | 2023-09-30 | (176.74M) | -234.9% |
| FY2022 | 2022-09-30 | (52.78M) | — |
Capital Expenditures vs competitors
How ARWR compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -47.1% is the lowest of 6, against a peer median of +29.1%.
- Capital expenditures amounts to 2.7% of revenue for ARWR, versus a peer median of 4.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $91.95M USD | +151.6% | -6.6% | 1.9% | |
| LTM Sep 2026 | $71.85M USD | +29.1% | +36.8% | 7.5% | |
| LTM Sep 2026 | $12M USD | -47.1% | -59.2% | 2.7% | |
| LTM Mar 2026 | $981.99K USD | +43.1% | -19.2% | 1.4% | |
| LTM Mar 2026 | €955.79K EUR | +5.0% | +11.4% | 7.1% | |
| LTM Mar 2026 | $318.66K USD | -41.5% | -69.0% | 0.7% | |
| LTM Mar 2026 | $106K USD | — | -53.4% | 11.5% | |
| Peer median (excluding ARWR) | — | +29.1% | -12.9% | 4.5% | |
Competitors are the stored peer set for ARWR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 | FY2026 Sep 2026 |
|---|---|---|---|---|---|
| Net Income | (176.49M) | (209.28M) | (609.69M) | 30.11M | (717.13M) |
| Depreciation & Amortization | 10.42M | 12.49M | 18.6M | 23.93M | 26.62M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 120.89M | 78.13M | 73.97M | 63.37M | 68.15M |
| Change in Working Capital | (98.29M) | (51.55M) | 25.09M | (18.24M) | 60.9M |
| Accounts Receivables | 8.85M | 1.41M | 0 | (56.97M) | (3.29M) |
| Inventory | 0 | 0 | 0 | 0 | (9.08M) |
| Accounts Payables | (6.59M) | 33M | (5.54M) | 6.29M | 12.48M |
| Other Working Capital | (100.55M) | (85.96M) | 30.63M | 32.45M | 60.78M |
| Other Non-Cash Items | 7.34M | 16.31M | 29.19M | 80.38M | 289.52M |
| Operating Cash Flow | (136.13M) | (153.89M) | (462.85M) | 179.55M | (271.95M) |
| Capital Expenditures | (52.78M) | (176.74M) | (141.47M) | (22.67M) | (12M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (223.39M) | (246.14M) | (720.95M) | (796.26M) | (1.14B) |
| Sales of Investments | 270.75M | 326.72M | 442.34M | 689.63M | 695.23M |
| Other Investing Activities | 0 | 0 | 0 | 0 | (215M) |
| Investing Cash Flow | (5.42M) | (96.16M) | (420.07M) | (129.29M) | (670.48M) |
| Debt Repayment | 0 | 0 | 392M | (191.37M) | 578.52M |
| Common Stock Issued | 5.19M | 3.05M | 431.65M | 270.37M | 305.41M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 60M | 250M | 46.87M | (5M) | (107.12M) |
| Financing Cash Flow | 65.19M | 253.05M | 870.52M | 74.01M | 776.82M |
| Effect of Forex Changes | (67K) | (122K) | 4.2M | (401K) | 1.8M |
| Net Change in Cash | (76.43M) | 2.89M | (8.21M) | 123.86M | (163.81M) |
| Free Cash Flow | (188.91M) | (330.63M) | (604.32M) | 156.89M | (283.94M) |
Arrowhead Pharmaceuticals, Inc.
NASDAQ:ARWR
Intrinsic Alpha fair value
Locked
Current Price
$43.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.